Opinion: The pharmacometrics of infectious disease

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 8, 2013, Pages

  Davies, G R ^a   Hope, W ^a   Khoo, S ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; ARTEMISININ; DAPTOMYCIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; QUINOLONE DERIVATIVE; RIBAVIRIN; VANCOMYCIN;

ACUTE DISEASE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BLOODSTREAM INFECTION; CLINICAL PRACTICE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG RESEARCH; DRUG TARGETING; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IN VITRO STUDY; INFECTION; INTENSIVE CARE; MALARIA; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; NONHUMAN; OPPORTUNISTIC INFECTION; PARASITE CLEARANCE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; TREATMENT DURATION; VIRUS INFECTION;

EID: 84883397495     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.46     Document Type: Review

References (12)

1. Ambrose, P.G., Grasela, D.M., Grasela, T.H., Passarell, J., Mayer, H.B. & Pierce, P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45, 2793-2797 (2001).
2. Arbeit, R.D., Maki, D., Tally, F.P., Campanaro, E. & Eisenstein, B.I.; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin. Infect. Dis. 38, 1673-1681 (2004).
3. Kullar, R., Davis, S.L., Levine, D.P. & Rybak, M.J. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52, 975-981 (2011).
4. Diacon, A.H. et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother. 56, 3027-3031 (2012).
5. Longley, N. et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin. Infect. Dis. 47, 1556-1561 (2008).
6. Gonzalez de Requena, D. et al. Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. J. Antimicrob. Chemother. 66, 192-200 (2011).
7. Jin, R., Fossler, M.J., McHutchison, J.G., Howell, C.D. & Dowling, T.C. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J. 14, 571-580 (2012).
8. Stepniewska, K. & White, N.J. Pharmacokinetic determinants of the window of selection for antimalarial drug resistance. Antimicrob. Agents Chemother. 52, 1589-1596 (2008).
9. Dixit, N.M. & Perelson, A.S. Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J. Theor. Biol. 226, 95-109 (2004).
10. Saralamba, S. et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U.S.A. 108, 397-402 (2011).
11. Hope, W.W. et al. Software for dosage individualization of voriconazole for immunocompromised patients. Antimicrob. Agents Chemother. 57, 1888-1894 (2013).
12. Parienti, J.J. et al. Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial. Antimicrob. Agents Chemother. 57, 2265-2271 (2013).